4 completed, 1 terminated. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Terminated 1 |
Follow scyllitol: new trials by email Literature Review of scyllitol trials Research Report on scyllitol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia ELND005, Placebo - Down Syndrome | Phase 2 | Completed | OPKO Health, Inc. | 23 | 2013-09-01 | 2019-11-04 |
| Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease ELND005, Placebo - Alzheimer's Disease | Phase 2 | Completed | OPKO Health, Inc. | 350 | 2012-11-01 | 2019-10-21 |
| Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder ELND005, Lamotrigine, Valproic acid - Bipolar 1 Disorder | Phase 2 | Terminated | OPKO Health, Inc. | 309 | 2012-08-01 | 2019-10-21 |
| ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease ELND005 (scyllo-inositol) - Alzheimer's Disease | Phase 2 | Completed | OPKO Health, Inc. | 103 | 2009-06-01 | 2019-10-21 |
| ELND005 in Patients With Mild to Moderate Alzheimer's Disease Placebo Control, ELND005 - Alzheimer Disease | Phase 2 | Completed | OPKO Health, Inc. | 353 | 2007-12-01 | 2019-11-01 |
Alzheimer Disease (3) · Aggression (1) · Down Syndrome (1) · Psychomotor Agitation (1)
United States (5) · Canada (4) · Spain (2) · Bulgaria (1) · Czechia (1) · France (1) · Poland (1) · Romania (1) · Turkey (Türkiye) (1) · United Kingdom (1)